Alzheimer’s Foundation Awards Feinstein Institute Grant to Study Aggression in Alzheimer’s Disease

MANHASSET, NY – Feinstein Institute for Medical Research scientists Peter Davies, PhD, and Jeremy L. Koppel, MD, were awarded a five-year, $500,000 grant from the Alzheimer’s Foundation of America (AFA) to explore psychosis and aggression in individuals living with Alzheimer’s disease. This is one of the largest research grants AFA has ever awarded.

“When considering what research projects we should fund, the uniqueness of Dr. Davies’ and Dr. Koppel’s project struck a chord with us,” said Charles J. Fuschillo, Jr., AFA’s president and chief executive officer. “The types of behaviors they’re studying are a leading reason that families transition loved ones from home to skilled care settings. To be able to uncover why these symptoms occur — and to prevent or treat them — would offer solace to so many people.”

Alzheimer’s disease is the most common form of dementia, typically occurring in older individuals over the age of 65. Symptoms include loss of memory and other intellectual functions, which disrupt daily living. Up to 50 percent of people with Alzheimer’s disease experience psychosis, which may include paranoia and other delusions in addition to hallucinations. People experiencing Alzheimer’s disease and psychosis progress more rapidly through the stages of the disease and are more likely to be violent. While at home, spouses, and adult children are often the victims of this aggression, and it is a major reason for transition to care settings. In institutional settings, such as skilled nursing facilities, the violence can continue and may be directed towards other residents or staff. Currently, safe and effective treatments for this form of the disease are lacking.

With this study, Drs. Davies and Koppel are looking to understand what makes Alzheimer’s disease patients so susceptible to psychosis and aggression in the hopes of leveraging those discoveries into the development of effective therapies. Drs. Davies and Koppel believe that psychosis in Alzheimer’s disease may be the result of the regional distribution in the brain of one of the hallmarks of the disease, tangles of tau proteins. The researchers believe that when these tangles are disproportionally distributed to articular portions of the brain, there is a greater probability of psychosis and aggression.

“We are honored the Alzheimer’s Foundation of America is supporting our study to better understand what causes the emergence of such troubling behaviors in previously gentle people,” said Dr. Davies. “Through this research, we hope to develop antibody-based medications to treat tangles in the brain, helping reduce the effects of the disease and associated psychosis and aggression.”

Kevin J. Tracey, MD, president and CEO of the Feinstein Institute said, “This outstanding recognition of Dr. Davies and Dr. Koppel by the Alzheimer’s Foundation reflects their success and leadership in the field. Unraveling the molecular mechanisms of Alzheimer’s disease is a fundamental step towards developing new therapies needed by millions of current and future patients.”

About The Feinstein Institute

The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest healthcare provider in New York. Home to 50 research laboratories and to clinical research throughout dozens of hospitals and outpatient facilities, the 2,000 researchers and staff of the Feinstein are making breakthroughs in molecular medicine, genetics, oncology, brain research, mental health, autoimmunity, and bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we empower imagination and pioneer discovery, visit FeinsteinInstitute.org.

About the Alzheimer’s Foundation of America (AFA)

The Alzheimer’s Foundation of America, based in New York, is a non-profit organization that unites more than 2,600 member organizations nationwide with the goal of providing optimal care and services to individuals living with dementia, and to their caregivers and families. Its services include a national, toll-free helpline (866-232-8484) staffed by licensed social workers, educational conferences and materials, a free quarterly magazine for caregivers, the National Memory Screening program, and “AFA Partners in Care” dementia care training for healthcare professionals. For more information about AFA, call 866-232-8484, visit www.alzfdn.org, follow us on Twitter, or connect with us on Facebook or LinkedIn.

For media inquiries, please contact:
Heather Ball
Phone: +1 (516) 562-0325
Email: hball@northwell.edu

Tags: